Media coverage about Genocea Biosciences (NASDAQ:GNCA) has been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Genocea Biosciences earned a coverage optimism score of 0.05 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 43.303732813471 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the media stories that may have effected Accern’s analysis:

Genocea Biosciences (NASDAQ:GNCA) traded down $0.05 during trading on Tuesday, hitting $1.13. 323,909 shares of the stock traded hands, compared to its average volume of 581,293. Genocea Biosciences has a 52-week low of $1.03 and a 52-week high of $7.29. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of 2.51.

Genocea Biosciences (NASDAQ:GNCA) last released its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.59) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.08). During the same quarter last year, the company earned ($0.45) earnings per share. sell-side analysts anticipate that Genocea Biosciences will post -1.91 earnings per share for the current year.

A number of equities analysts have issued reports on GNCA shares. Piper Jaffray Companies reiterated an “overweight” rating and issued a $5.00 price objective on shares of Genocea Biosciences in a research note on Thursday, November 2nd. Zacks Investment Research upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a research note on Monday, October 16th. Stifel Nicolaus downgraded Genocea Biosciences from a “buy” rating to a “hold” rating and dropped their price objective for the company from $15.00 to $2.50 in a research note on Monday, September 25th. Needham & Company LLC downgraded Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Finally, Cowen reiterated a “buy” rating and issued a $10.00 price objective on shares of Genocea Biosciences in a research note on Tuesday, September 26th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $6.06.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Genocea Biosciences (GNCA) Share Price” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/05/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-genocea-biosciences-gnca-share-price.html.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Insider Buying and Selling by Quarter for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Stock Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related stocks with our FREE daily email newsletter.